Age-related macular degeneration (AMD) is the leading cause of vision loss for people over 65. We have excellent treatments for the wet form of AMD. But until recently, we haven’t had any therapeutics ...

Please provide your email address to receive an email when new articles are posted on . A study presented at Angiogenesis, Exudation, and Degeneration 2024 provided insights on how geographic atrophy ...

Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "Geographic Atrophy Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...

Pegcetacoplan, an investigational complement factor inhibitor that has the potential to be the first FDA–approved treatment for geographic atrophy in dry age-related macular degeneration (AMD), ...

On February 17, the U.S. Food and Drug Administration (FDA) gave the go-ahead for pegcetacoplan, to be marketed as Syfovre, bringing new hope to people diagnosed with geographic atrophy (GA), also ...

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...

Geographic atrophy (GA) is one of two kinds of advanced age-related macular degeneration (AMD). It’s an eye disease that damages cells in the central part of your retina called the macula. Late-stage ...

—With a greater number of treatments available for age-related macular degeneration (AMD), it’s more important than ever that patients’ progression of geographic atrophy (GA) secondary to AMD is ...

New data on oral minocycline answer a long-held question about the drug's potential to help with geographic atrophy. The immune-targeting drug didn't slow the atrophy's expansion across the macula, ...

Please provide your email address to receive an email when new articles are posted on . Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic ...